199 related articles for article (PubMed ID: 20948320)
21. Tumor-associated macrophages, epidermal growth factor receptor correlated with the triple negative phenotype in endometrial endometrioid adenocarcinoma.
Jiang XF; Tang QL; Shen XM; Li HG; Chen LH; Wang XY; Luo X; Lin ZQ; Jiang GY
Pathol Res Pract; 2012 Dec; 208(12):730-5. PubMed ID: 23122929
[TBL] [Abstract][Full Text] [Related]
22. Tumor-associated macrophages correlate with progesterone receptor loss in endometrial endometrioid adenocarcinoma.
Jiang XF; Tang QL; Li HG; Shen XM; Luo X; Wang XY; Lin ZQ
J Obstet Gynaecol Res; 2013 Apr; 39(4):855-63. PubMed ID: 23106983
[TBL] [Abstract][Full Text] [Related]
23. Combined application of anti-VEGF and anti-EGFR attenuates the growth and angiogenesis of colorectal cancer mainly through suppressing AKT and ERK signaling in mice model.
Ding C; Li L; Yang T; Fan X; Wu G
BMC Cancer; 2016 Oct; 16(1):791. PubMed ID: 27729020
[TBL] [Abstract][Full Text] [Related]
24. Blockade of EphA receptor tyrosine kinase activation inhibits vascular endothelial cell growth factor-induced angiogenesis.
Cheng N; Brantley DM; Liu H; Lin Q; Enriquez M; Gale N; Yancopoulos G; Cerretti DP; Daniel TO; Chen J
Mol Cancer Res; 2002 Nov; 1(1):2-11. PubMed ID: 12496364
[TBL] [Abstract][Full Text] [Related]
25. EphA2-dependent molecular targeting therapy for malignant tumors.
Biao-xue R; Xi-guang C; Shuan-ying Y; Wei L; Zong-juan M
Curr Cancer Drug Targets; 2011 Nov; 11(9):1082-97. PubMed ID: 21933105
[TBL] [Abstract][Full Text] [Related]
26. [Relationships between the molecular biomarkers and the clinicopathologic features and prognosis in endometrial carcinoma].
Yao YY; Xu WZ; Wang Y; Shen DH; Wang JL; Wei LH
Beijing Da Xue Xue Bao Yi Xue Ban; 2011 Oct; 43(5):743-8. PubMed ID: 22008688
[TBL] [Abstract][Full Text] [Related]
27. Starving tumors: inhibition of glycolysis reduces viability of human endometrial and ovarian cancer cells and enhances antitumor efficacy of GnRH receptor-targeted therapies.
Reutter M; Emons G; Gründker C
Int J Gynecol Cancer; 2013 Jan; 23(1):34-40. PubMed ID: 23154267
[TBL] [Abstract][Full Text] [Related]
28. EphA2-induced angiogenesis in ewing sarcoma cells works through bFGF production and is dependent on caveolin-1.
Sáinz-Jaspeado M; Huertas-Martinez J; Lagares-Tena L; Martin Liberal J; Mateo-Lozano S; de Alava E; de Torres C; Mora J; Del Muro XG; Tirado OM
PLoS One; 2013; 8(8):e71449. PubMed ID: 23951165
[TBL] [Abstract][Full Text] [Related]
29. [Significance of phosphoinositide 3 kinase/AKT pathway alterations in endometrial carcinoma].
Yang X; Dong Y; Zhang XM; Liang Y; Zhang Y; Meng YT; Wang Y; Wang W; Nong L; Li T; Liao QP
Zhonghua Bing Li Xue Za Zhi; 2011 Dec; 40(12):799-804. PubMed ID: 22336203
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of VEGF-dependent multistage carcinogenesis by soluble EphA receptors.
Cheng N; Brantley D; Fang WB; Liu H; Fanslow W; Cerretti DP; Bussell KN; Reith A; Jackson D; Chen J
Neoplasia; 2003; 5(5):445-56. PubMed ID: 14670182
[TBL] [Abstract][Full Text] [Related]
31. Anti-MUC1 monoclonal antibody (C595) and docetaxel markedly reduce tumor burden and ascites, and prolong survival in an in vivo ovarian cancer model.
Wang L; Chen H; Pourgholami MH; Beretov J; Hao J; Chao H; Perkins AC; Kearsley JH; Li Y
PLoS One; 2011; 6(9):e24405. PubMed ID: 21931707
[TBL] [Abstract][Full Text] [Related]
32. Should grade 3 endometrioid endometrial carcinoma be considered a type 2 cancer-a clinical and pathological evaluation.
Voss MA; Ganesan R; Ludeman L; McCarthy K; Gornall R; Schaller G; Wei W; Sundar S
Gynecol Oncol; 2012 Jan; 124(1):15-20. PubMed ID: 21864888
[TBL] [Abstract][Full Text] [Related]
33. PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy.
Bian X; Gao J; Luo F; Rui C; Zheng T; Wang D; Wang Y; Roberts TM; Liu P; Zhao JJ; Cheng H
Oncogene; 2018 Jan; 37(3):341-351. PubMed ID: 28945226
[TBL] [Abstract][Full Text] [Related]
34. Dual targeting of EphA2 and FAK in ovarian carcinoma.
Shahzad MM; Lu C; Lee JW; Stone RL; Mitra R; Mangala LS; Lu Y; Baggerly KA; Danes CG; Nick AM; Halder J; Kim HS; Vivas-Mejia P; Landen CN; Lopez-Berestein G; Coleman RL; Sood AK
Cancer Biol Ther; 2009 Jun; 8(11):1027-34. PubMed ID: 19395869
[TBL] [Abstract][Full Text] [Related]
35. Association of Hormone Receptor Expression with Survival in Ovarian Endometrioid Carcinoma: Biological Validation and Clinical Implications.
Rambau P; Kelemen LE; Steed H; Quan ML; Ghatage P; Köbel M
Int J Mol Sci; 2017 Feb; 18(3):. PubMed ID: 28264438
[TBL] [Abstract][Full Text] [Related]
36. Downregulation of FOXO1 mRNA levels predicts treatment failure in patients with endometrial pathology conservatively managed with progestin-containing intrauterine devices.
Reyes HD; Carlson MJ; Devor EJ; Zhang Y; Thiel KW; Samuelson MI; McDonald M; Yang S; Stephan JM; Savage EC; Dai D; Goodheart MJ; Leslie KK
Gynecol Oncol; 2016 Jan; 140(1):152-60. PubMed ID: 26524723
[TBL] [Abstract][Full Text] [Related]
37. [EphA2 promotes angiogenesis and metastasis of head and neck squamous cell carcinoma in vivo].
Liu Y; Zhang X; Yu CY; Qiu YZ; Huang DH; Zhou XJ; Tan PQ; Xiao JY; Tian YQ
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2012 Jan; 47(1):53-7. PubMed ID: 22455776
[TBL] [Abstract][Full Text] [Related]
38. EphA2 as a target for ovarian cancer therapy.
Landen CN; Kinch MS; Sood AK
Expert Opin Ther Targets; 2005 Dec; 9(6):1179-87. PubMed ID: 16300469
[TBL] [Abstract][Full Text] [Related]
39. Old and new perspectives in the pharmacological treatment of advanced or recurrent endometrial cancer: Hormonal therapy, chemotherapy and molecularly targeted therapies.
Gadducci A; Cosio S; Genazzani AR
Crit Rev Oncol Hematol; 2006 Jun; 58(3):242-56. PubMed ID: 16436330
[TBL] [Abstract][Full Text] [Related]
40. EphA2 overexpression promotes ovarian cancer growth.
Lu C; Shahzad MM; Wang H; Landen CN; Kim SW; Allen J; Nick AM; Jennings N; Kinch MS; Bar-Eli M; Sood AK
Cancer Biol Ther; 2008 Jul; 7(7):1098-103. PubMed ID: 18443431
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
